Dosing | COSENTYX® (secukinumab)

Get patients started with COSENTYX^® (secukinumab) successfully

Suggested SC COSENTYX dosing and prescribing approaches for appropriate adult and pediatric patients¹

Adults with PsO and PsA

Adults with PsA

Adults with AS or nr-axSpA

Children with JPsA and ERA

Graphic showing prescription for loading dose and maintenance dose.

COSENTYX Suggested Prescribing Approaches

COSENTYX is administered subcutaneously. COSENTYX is intended for use under the guidance and supervision of a physician. Adult patients may be injected by a caregiver or self-administer COSENTYX after proper training in subcutaneous injection technique using the Sensoready^® pen or prefilled syringe. Pediatric patients should not self-administer COSENTYX using the Sensoready pen or prefilled syringe. An adult caregiver should prepare and inject COSENTYX after receiving training on the right way to prepare and inject COSENTYX.¹

Easy-to-remember dosing schedule

COSENTYX loading dose* followed by maintenance dose (once every 4 weeks)¹

The last loading dose can be covered in the first maintenance dose prescription

Graphic showing the easy-to-remember dosing schedule.

*Loading dose at Weeks 0, 1, 2, 3, and 4.

COSENTYX can be used alone or with methotrexate¹

Recommended dosage per indication¹

Graph showing recommended dosage for children.

COSENTYX is administered subcutaneously. COSENTYX is intended for use under the guidance and supervision of a physician. Adult patients may be injected by a caregiver of self-administer COSENTYX after proper training in subcutaneous injection technique using the Sensoready pen or prefilled syringe. Pediatric patients should not self-administer COSENTYX using the Sensoready pen or prefilled syringe. An adult caregiver should prepare and inject COSENTYX after receiving training on the right way to prepare and inject COSENTYX.¹

Tap to see IMPORTANT SAFETY INFORMATION and INDICATIONS

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS
COSENTYX is contraindicated in patients with a previous serious hypersensitivity reaction to secukinumab or to any of the excipients in COSENTYX. Cases of anaphylaxis have been reported during treatment with COSENTYX...

CONTRAINDICATIONS

COSENTYX is contraindicated in patients with a previous serious hypersensitivity reaction to secukinumab or to any of the excipients in COSENTYX. Cases of anaphylaxis have been reported during treatment with COSENTYX.

WARNINGS AND PRECAUTIONS

Infections

COSENTYX may increase the risk of infections. In clinical trials, a higher rate of infections was observed in COSENTYX treated subjects compared to placebo-treated subjects. In placebo-controlled clinical trials in subjects with moderate to severe PsO, higher rates of common infections, such as nasopharyngitis (11.4% versus 8.6%), upper respiratory tract infection (2.5% versus 0.7%) and mucocutaneous infections with candida (1.2% versus 0.3%) were observed in subjects treated with COSENTYX compared to placebo-treated subjects. A similar increase in risk of infection in subjects treated with COSENTYX was seen in placebo-controlled trials in subjects with PsA, AS and nr-axSpA. The incidence of some types of infections, including fungal infections, appeared to be dose-dependent in clinical trials.

In the postmarketing setting, serious and some fatal infections have been reported in patients treated with COSENTYX.

Exercise caution when considering the use of COSENTYX in patients with a chronic infection or a history of recurrent infection. Instruct patients to seek medical advice if signs or symptoms suggestive of an infection occur. If a patient develops a serious infection, monitor the patient closely and discontinue COSENTYX until the infection resolves.

Pre-treatment Evaluation for Tuberculosis

Evaluate patients for tuberculosis (TB) infection prior to initiating treatment with COSENTYX. Avoid administration of COSENTYX to patients with active TB infection. Initiate treatment of latent TB prior to administering COSENTYX. Consider anti-TB therapy prior to initiation of COSENTYX in patients with a past history of latent or active TB in whom an adequate course of treatment cannot be confirmed. Monitor patients closely for signs and symptoms of active TB during and after treatment.

Inflammatory Bowel Disease

Inflammatory Bowel Disease (IBD) exacerbations, in some cases serious and/or leading to discontinuation of COSENTYX, occurred in COSENTYX treated subjects during clinical trials in PsO, PsA, AS, nr-axSpA, and HS. In adult subjects with HS, the incidence of IBD was higher in subjects who received COSENTYX 300 mg every 2 weeks (Ulcerative Colitis [UC] 1 case, EAIR 0.2/100 subject-years; Crohn’s Disease [CD] 1 case, EAIR 0.2/100 subject-years) compared to subjects who received COSENTYX 300 mg every 4 weeks (IBD 1 case, EAIR 0.2/100 subject-years). In addition, new onset IBD cases occurred in subjects treated with COSENTYX in clinical trials. In an exploratory trial in 59 subjects with active Crohn’s disease [COSENTYX is not approved for the treatment of Crohn’s disease], there were trends toward greater disease activity and increased adverse reactions in subjects treated with COSENTYX as compared to placebo-treated subjects.

Exercise caution when prescribing COSENTYX to patients with IBD. Patients treated with COSENTYX should be monitored for signs and symptoms of IBD.

Eczematous Eruptions

In postmarketing reports, cases of severe eczematous eruptions, including atopic dermatitis-like eruptions, dyshidrotic eczema, and erythroderma, were reported in patients receiving COSENTYX; some cases resulted in hospitalization. The onset of eczematous eruptions was variable, ranging from days to months after the first dose of COSENTYX.

Treatment may need to be discontinued to resolve the eczematous eruption. Some patients were successfully treated for eczematous eruptions while continuing COSENTYX.

Hypersensitivity Reactions

Anaphylaxis and cases of urticaria occurred in COSENTYX treated subjects in clinical trials. If an anaphylactic or other serious allergic reaction occurs, administration of COSENTYX should be discontinued immediately and appropriate therapy initiated.

The removable caps of the COSENTYX Sensoready^® pen and the COSENTYX 1 mL and 0.5 mL prefilled syringes contain natural rubber latex, which may cause an allergic reaction in latex-sensitive individuals. The safe use of the COSENTYX Sensoready pen or prefilled syringe in latex-sensitive individuals has not been studied.

Immunizations

Prior to initiating therapy with COSENTYX, consider completion of all age-appropriate immunizations according to current immunization guidelines. COSENTYX may alter a patient’s immune response to live vaccines. Avoid use of live vaccines in patients treated with COSENTYX.

MOST COMMON ADVERSE REACTIONS

Most common adverse reactions (>1%) are nasopharyngitis, diarrhea, and upper respiratory tract infection.

Please see Full Prescribing Information, including Medication Guide.

10/23 310615

Get patients started with COSENTYX® (secukinumab) successfully

Suggested SC COSENTYX dosing and prescribing approaches for appropriate adult and pediatric patients1

Easy-to-remember dosing schedule

COSENTYX loading dose* followed by maintenance dose (once every 4 weeks)1

Recommended dosage per indication1

Learn about a positive injection experience with COSENTYXo

Support to help offices help patients

COSENTYX® Connect Team Members help patients start and stay on track

Definitions and references

Get patients started with COSENTYX^® (secukinumab) successfully

Suggested SC COSENTYX dosing and prescribing approaches for appropriate adult and pediatric patients¹

COSENTYX loading dose* followed by maintenance dose (once every 4 weeks)¹

Recommended dosage per indication¹

Learn about a positive injection experience with COSENTYX^o

COSENTYX^® Connect Team Members help patients start and stay on track